Literature DB >> 2426262

The kinetics of inhibition of alpha-thrombin in human plasma.

J Jesty.   

Abstract

Methods have been developed for kinetic studies of the inhibition of exogenous unmodified thrombin in human plasma containing normal levels of fibrinogen and calcium ion. To prevent interference by other proteases, factor VIII-deficient plasma was used and contained 50 nM Phe-Phe-Arg-chloromethyl ketone and 1 kallikrein-inactivating unit/ml aprotinin; neither inhibited thrombin at these levels. Two independent assays were used. The first was the discontinuous amidolytic assay of thrombin activity, which measures both free thrombin and thrombin-alpha 2-macroglobulin complex, and was used to estimate the rates of inhibition both by "inactivating" inhibitors, such as anti-thrombin and alpha 1-protease inhibitor, and by alpha 2-macroglobulin (alpha 2M). The contribution of alpha 2M was confirmed by a second method, which measured with time the generation of amidolytic activity due to the thrombin-alpha 2M complex. The total rate of thrombin inhibition in plasma containing 4 mM free Ca2+ was of the order of 1.9 min-1, of which 0.4 min-1 was due to alpha 2M and 0.9 min-1 was due to inhibitors that were removed when plasma was passed through heparin-agarose. Thrombin inhibition was also measured in varying dilutions of plasma and confirmed that total inhibition rate is approximately linearly related to plasma (and thus inhibitor) concentration. Negatively charged phospholipid micelles had very little effect on thrombin inhibition rate, but platelets accelerated inhibition to more than 2.5 min-1.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2426262

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Delivery of water-soluble drugs using acoustically triggered perfluorocarbon double emulsions.

Authors:  Mario L Fabiilli; James A Lee; Oliver D Kripfgans; Paul L Carson; J Brian Fowlkes
Journal:  Pharm Res       Date:  2010-09-25       Impact factor: 4.200

2.  Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.

Authors:  P J Hogg; C M Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

3.  Binding of thrombin to subendothelial extracellular matrix. Protection and expression of functional properties.

Authors:  R Bar-Shavit; A Eldor; I Vlodavsky
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

4.  Novel magnetic fibrin hydrogel scaffolds containing thrombin and growth factors conjugated iron oxide nanoparticles for tissue engineering.

Authors:  Ofra Ziv-Polat; Hadas Skaat; Abraham Shahar; Shlomo Margel
Journal:  Int J Nanomedicine       Date:  2012-03-06

5.  Moderate plasma dilution using artificial plasma expanders shifts the haemostatic balance to hypercoagulation.

Authors:  Elena I Sinauridze; Alexander S Gorbatenko; Elena A Seregina; Elena N Lipets; Fazoil I Ataullakhanov
Journal:  Sci Rep       Date:  2017-04-12       Impact factor: 4.379

6.  Decreased prothrombin conversion and reduced thrombin inactivation explain rebalanced thrombin generation in liver cirrhosis.

Authors:  Romy M W Kremers; Marie-Claire Kleinegris; Marisa Ninivaggi; Bas de Laat; Hugo Ten Cate; Ger H Koek; Rob J Wagenvoord; H Coenraad Hemker
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.